Topics, Trends & Updates
October 2021
PrEP Aware Week: October 25 to 31, 2021

Dear Colleague,

The AIDS Institute is pleased to announce that the third annual PrEP Aware Week will be held this year from October 25 to October 31.  With your support, we anticipate that 2021 will be our most exciting and engaging PrEP Aware Week yet!

PrEP Aware Week 2021 will feature a diverse panel of community PrEP Ambassadors discussing the theme: "My PrEP.” This theme emphasizes that PrEP can be tailored to support each individual’s sexual health and HIV prevention needs. In the coming weeks you will hear more about the exciting messages that these ambassadors have developed under the theme of: “My PrEP”!

Stay tuned! In the coming weeks the AIDS Institute will share:
  • Details about a statewide webinar to introduce the new 2021 ambassadors and explore ideas for participating in PrEP Aware Week
  • A Social Media Toolkit that includes short videos, ads and posts
  • Email signatures and zoom backgrounds
  • A PrEP Materials Order form for brochures, booklets, and more!

If you have any questions or suggestions for PrEP Aware Week, please email us at
Updated Guidelines
Selecting an Initial ART Regimen
Summary of Updates:

New recommendation regarding 2-drug initial ART: With the exception of dolutegravir/ lamivudine/(DTG/3TC), clinicians should not prescribe 2-drug regimens as initial ART. (A3) Clinicians should prescribe DTG/3TC only after:
  • HIV resistance and hepatitis B virus (HBV) status are known. (A1)
  • Genotypic resistance testing results have confirmed that a patient does not have a major reverse transcriptase mutation, including the M184V/I resistance mutation. DTG/3TC is contraindicated in patients with these resistance-associated mutations. (A1)

TDF vs TAF: The MCCC now recommends either formulation of tenofovir (TAF or TDF) as part of the backbone for preferred initiation ART regimens. See the new table: Important Clinical Considerations With Either TDF/FTC or TAF/FTC as Initial Antiretroviral Therapy.

  • Added: Dolutegravir/lamivudine (DTG/3TC; Dovato).
  • Deleted: TAF 25 mg/FTC and DTG (Descovy and Tivicay); TAF 25 mg/FTC and RAL HD (Descovy and Isentress HD); TDF/FTC and DTG (Truvada and Tivicay); TDF/FTC and RAL HD (Truvada and Isentress HD)

Related Guideline Updates: Rapid ART and HIV-2
When to Initiate ART, With Protocol for Rapid Initiation, October 2021 updates:

  • 2-drug ART not recommended for rapid ART: Dolutegravir/lamivudine (DTG/3TC) cannot be used for rapid ART because a baseline HIV genotypic resistance profile and HBV status are required prior to prescription of this regimen.
  • Removed from preferred regimens: Tenofovir alafenamide/emtricitabine and raltegravir (TAF 25 mg/FTC and RAL HD; Descovy and Isentress HD).

Diagnosis and Management of HIV-2 in Adults, October 2021 updates:

Hot Topics
CEI Highlights
PrEP for Transgender
and Gender-Diverse People
Join Dr. Asa Radix of Callen Lorde Community Health Center for this PrEP Aware Week webinar from CEI.

  • Date: October 29, 2021
  • Time: 10:00 to 11:00 AM
  • Learning Objectives: (1) Describe barriers to PrEP among transgender and gender-diverse people. (2) Summarize the evidence for PrEP for transgender and gender-diverse people. (3) Discuss the importance of affirming care. (4) Identify ways to overcome PrEP barriers for trans people.
  • Download flyer | Register online
New Video Series: Trans Health
Join Dr. Erica Bostick and Dr. Kyan Lynch as they discuss the ins and outs of TGNC health in a series of short videos, all saved in 1 YouTube playlist. Watch Now
Upcoming Training, Education, and Events
Are You a Subscriber?
If this newsletter was forwarded to you, please subscribe now to make sure you receive the Clinical Guidelines Program news every month and stay current with new and updated guidelines.

Subscribing is as easy as entering your email address. We will send you just 1 email per month, and we do not share our mailing list.
Please subscribe now!
Comment? Question? Suggestion? Drop us a line: We welcome feedback and suggestions, and if you send us a question, we will get back to you as quickly as possible. Please note, however, that we cannot answer questions about the care or treatment of specific patients and cannot provide clinical advice. 

Provide feedback: Take our brief survey now.